Covetrus in Talks to Acquire Cencora's Veterinary Business
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 02 2026
0mins
Source: seekingalpha
- Acquisition Talks Initiated: Covetrus is in preliminary discussions to acquire Cencora's veterinary business, a move that could further solidify Covetrus's position in the veterinary tech market and enhance its market share.
- Financing Arrangements: Covetrus's owners, CD&R and TPG, are negotiating with private credit firms like Blue Owl Capital to secure approximately $3 billion in new debt, aimed at refinancing Covetrus's existing $2 billion debt and supporting the potential acquisition.
- Privatization Background: CD&R and TPG took Covetrus private in 2022 in a deal valued at about $4 billion, and this acquisition negotiation reflects their ongoing commitment to investing in the veterinary market, potentially laying the groundwork for future growth.
- Market Reaction: Although CD&R, TPG, Cencora, and Blue Owl declined to comment, the market holds a cautiously optimistic view on Covetrus's acquisition plans, believing it will enhance its financial stability and competitive edge.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy COR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on COR
Wall Street analysts forecast COR stock price to rise
9 Analyst Rating
8 Buy
1 Hold
0 Sell
Strong Buy
Current: 274.910
Low
400.00
Averages
415.38
High
440.00
Current: 274.910
Low
400.00
Averages
415.38
High
440.00
About COR
Cencora, Inc. is a global pharmaceutical sourcing and distribution services company. The Company helps both healthcare providers and pharmaceutical and biotech manufacturers improve patient access to products and enhance patient care. The Company operates through two segments: U.S. Healthcare Solutions and International Healthcare Solutions. The U.S. Healthcare Solutions segment distributes a comprehensive offering of brand-name, specialty brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to a variety of healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, long-term care and alternate site pharmacies, and other customers. The International Healthcare Solutions segment consists of businesses that focus on international pharmaceutical wholesale and related service operations and global commercialization services.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Cencora Raises Fiscal 2026 Earnings Outlook Amid Share Buybacks
- Earnings Outlook Raised: Cencora has raised its adjusted diluted earnings per share forecast for fiscal 2026 to a range of $17.70 to $17.90, up from the previous $17.65 to $17.90, indicating strong confidence in future performance.
- New Buyback Program: The company announced a new share repurchase program authorized by its board to buy back an additional $2.0 billion worth of common stock, further enhancing investor confidence in its growth prospects.
- Remaining Buyback Balance: Cencora has $382 million remaining under its existing buyback program authorized in May 2024, providing the company with flexibility to navigate market fluctuations.
- Positive Market Reaction: Shares of Cencora spiked in premarket trading, reflecting investor optimism regarding the company's earnings outlook and buyback plans, which may drive further stock price appreciation.
See More
Cencora Raises Fiscal 2026 Earnings Outlook
- Earnings Outlook Upgrade: Cencora Inc. has raised its fiscal 2026 adjusted earnings per share forecast to a range of $17.70 to $17.90, up from the previous range of $17.65 to $17.90, indicating increased confidence in future performance.
- Share Repurchase Authorization: The Board of Directors authorized an additional share repurchase program of up to $2.0 billion on May 20, aimed at enhancing shareholder value and market confidence through strategic buybacks.
- Repurchase Progress: The company completed $1 billion in share repurchases in May, with $382 million remaining under the previously authorized repurchase program as of May 21, showcasing proactive capital management strategies.
- Stock Price Reaction: In after-hours trading on the NYSE, Cencora's shares rose by 1.3% to $268.82, reflecting a positive market response to the upgraded earnings outlook.
See More
Cencora Authorizes $2 Billion Share Repurchase Program
- Share Repurchase Program: Cencora, Inc.'s Board of Directors has authorized a new $2 billion share repurchase program aimed at enhancing shareholder value through opportunistic buybacks, which is expected to positively impact the company's stock price.
- Financial Guidance Update: The company has raised its fiscal year 2026 adjusted diluted earnings per share guidance to a range of $17.70 to $17.90, up from the previous range of $17.65 to $17.90, reflecting confidence in future performance.
- Repurchase Progress: As of May 21, 2026, the company has $382 million remaining under the previously authorized repurchase program from May 2024, indicating active utilization of market opportunities to strengthen its capital structure.
- Investor Discussion Participation: Cencora will participate in upcoming investor discussions where the updated outlook for fiscal year 2026 will be elaborated, further bolstering market confidence in the company's growth potential.
See More
Cencora Under Investigation Amid Stock Plunge
- Disappointing Financial Results: Cencora reported second-quarter 2026 revenue of $78.3 billion, missing consensus estimates by $2.68 billion, which led to a downward revision of full-year revenue growth guidance to 4%-6%, indicating significant market challenges ahead for the company.
- Impact of Pricing Strategy: Management disclosed that manufactured price reductions resulted in a $2 billion revenue headwind during the quarter, a critical factor that directly affected the company's profitability and investor confidence.
- Stock Price Volatility: Following the earnings report, Cencora's stock plummeted by $53.16, or 17.4%, closing at $252.74 per share, reflecting investor concerns regarding the company's future outlook.
- Legal Investigation Initiated: Pomerantz LLP is investigating whether Cencora and its executives engaged in securities fraud or other unlawful business practices, which could further impact the company's reputation and shareholder interests.
See More
Cencora Under Investigation as Shares Plunge 17.4%
- Legal Investigation Launched: The Schall Law Firm has announced an investigation into Cencora, focusing on potential violations of securities laws, particularly whether the company issued false or misleading statements that could affect investor rights.
- Earnings Miss: Cencora's Q2 2026 financial results released on May 6 revealed that the company missed consensus estimates and lowered its full-year guidance, indicating significant financial pressure on the firm.
- Revenue Loss Impact: The company claimed that manufactured price reductions represented a $2 billion revenue headwind for the quarter, raising concerns among investors about the company's future performance.
- Severe Stock Reaction: Following this news, Cencora's shares fell by 17.4% on the same day, reflecting strong market concerns regarding the company's financial health and potentially prompting more investors to seek legal recourse.
See More
Cencora Under Investigation Amid Stock Plunge Following Earnings Miss
- Disappointing Financial Results: Cencora reported second-quarter 2026 revenue of $78.3 billion, missing consensus estimates by $2.68 billion, which led to a downward revision of its full-year revenue growth guidance to 4% to 6% from 7% to 9%.
- Impact of Price Adjustments: Management disclosed during the earnings call that manufactured list price reductions resulted in a $2 billion revenue headwind for the quarter, exacerbating investor concerns regarding the company's future performance.
- Stock Price Volatility: Following the earnings report on May 6, 2026, Cencora's stock price plummeted by $53.16, or 17.4%, closing at $252.74 per share, reflecting strong market apprehension about the company's financial health.
- Legal Investigation Initiated: Pomerantz LLP is investigating whether Cencora and its executives engaged in securities fraud or other unlawful business practices, which could have significant implications for the company's reputation and future legal liabilities.
See More
Cencora Raises Fiscal 2026 Earnings Outlook Amid Share Buybacks
- Earnings Outlook Raised: Cencora has raised its adjusted diluted earnings per share forecast for fiscal 2026 to a range of $17.70 to $17.90, up from the previous $17.65 to $17.90, indicating strong confidence in future performance.
- New Buyback Program: The company announced a new share repurchase program authorized by its board to buy back an additional $2.0 billion worth of common stock, further enhancing investor confidence in its growth prospects.
- Remaining Buyback Balance: Cencora has $382 million remaining under its existing buyback program authorized in May 2024, providing the company with flexibility to navigate market fluctuations.
- Positive Market Reaction: Shares of Cencora spiked in premarket trading, reflecting investor optimism regarding the company's earnings outlook and buyback plans, which may drive further stock price appreciation.
See More
Cencora Raises Fiscal 2026 Earnings Outlook
- Earnings Outlook Upgrade: Cencora Inc. has raised its fiscal 2026 adjusted earnings per share forecast to a range of $17.70 to $17.90, up from the previous range of $17.65 to $17.90, indicating increased confidence in future performance.
- Share Repurchase Authorization: The Board of Directors authorized an additional share repurchase program of up to $2.0 billion on May 20, aimed at enhancing shareholder value and market confidence through strategic buybacks.
- Repurchase Progress: The company completed $1 billion in share repurchases in May, with $382 million remaining under the previously authorized repurchase program as of May 21, showcasing proactive capital management strategies.
- Stock Price Reaction: In after-hours trading on the NYSE, Cencora's shares rose by 1.3% to $268.82, reflecting a positive market response to the upgraded earnings outlook.
See More
Cencora Authorizes $2 Billion Share Repurchase Program
- Share Repurchase Program: Cencora, Inc.'s Board of Directors has authorized a new $2 billion share repurchase program aimed at enhancing shareholder value through opportunistic buybacks, which is expected to positively impact the company's stock price.
- Financial Guidance Update: The company has raised its fiscal year 2026 adjusted diluted earnings per share guidance to a range of $17.70 to $17.90, up from the previous range of $17.65 to $17.90, reflecting confidence in future performance.
- Repurchase Progress: As of May 21, 2026, the company has $382 million remaining under the previously authorized repurchase program from May 2024, indicating active utilization of market opportunities to strengthen its capital structure.
- Investor Discussion Participation: Cencora will participate in upcoming investor discussions where the updated outlook for fiscal year 2026 will be elaborated, further bolstering market confidence in the company's growth potential.
See More
Cencora Under Investigation Amid Stock Plunge
- Disappointing Financial Results: Cencora reported second-quarter 2026 revenue of $78.3 billion, missing consensus estimates by $2.68 billion, which led to a downward revision of full-year revenue growth guidance to 4%-6%, indicating significant market challenges ahead for the company.
- Impact of Pricing Strategy: Management disclosed that manufactured price reductions resulted in a $2 billion revenue headwind during the quarter, a critical factor that directly affected the company's profitability and investor confidence.
- Stock Price Volatility: Following the earnings report, Cencora's stock plummeted by $53.16, or 17.4%, closing at $252.74 per share, reflecting investor concerns regarding the company's future outlook.
- Legal Investigation Initiated: Pomerantz LLP is investigating whether Cencora and its executives engaged in securities fraud or other unlawful business practices, which could further impact the company's reputation and shareholder interests.
See More
Cencora Under Investigation as Shares Plunge 17.4%
- Legal Investigation Launched: The Schall Law Firm has announced an investigation into Cencora, focusing on potential violations of securities laws, particularly whether the company issued false or misleading statements that could affect investor rights.
- Earnings Miss: Cencora's Q2 2026 financial results released on May 6 revealed that the company missed consensus estimates and lowered its full-year guidance, indicating significant financial pressure on the firm.
- Revenue Loss Impact: The company claimed that manufactured price reductions represented a $2 billion revenue headwind for the quarter, raising concerns among investors about the company's future performance.
- Severe Stock Reaction: Following this news, Cencora's shares fell by 17.4% on the same day, reflecting strong market concerns regarding the company's financial health and potentially prompting more investors to seek legal recourse.
See More
Cencora Under Investigation Amid Stock Plunge Following Earnings Miss
- Disappointing Financial Results: Cencora reported second-quarter 2026 revenue of $78.3 billion, missing consensus estimates by $2.68 billion, which led to a downward revision of its full-year revenue growth guidance to 4% to 6% from 7% to 9%.
- Impact of Price Adjustments: Management disclosed during the earnings call that manufactured list price reductions resulted in a $2 billion revenue headwind for the quarter, exacerbating investor concerns regarding the company's future performance.
- Stock Price Volatility: Following the earnings report on May 6, 2026, Cencora's stock price plummeted by $53.16, or 17.4%, closing at $252.74 per share, reflecting strong market apprehension about the company's financial health.
- Legal Investigation Initiated: Pomerantz LLP is investigating whether Cencora and its executives engaged in securities fraud or other unlawful business practices, which could have significant implications for the company's reputation and future legal liabilities.
See More
